Akari Therapeutics enters strategic ADC payload research collaboration with Whitehawk TherapeuticsPUBT·Jul 22 at 07:40 AMWHWK-3.13%AKTX-6.45%
Akari Therapeutics CEO Explains Why Growing Industry Demand for Next-Generation ADC Payloads Positions the Company at the Center of a Major Oncology OpportunityGlobeNewswire·Jul 22 at 07:40 AMAKTX-6.45%WHWK-3.13%
12 Health Care Stocks Moving In Tuesday's Pre-Market Sessionbenzinga_article·Jul 21 at 07:05 AMZYBT-3.89%IMNN-9.04%
Akari Therapeutics Enters Strategic Research Collaboration with Whitehawk Therapeutics | AKTX Stock NewsStockTitan·Jul 20 at 10:05 PMAKTX-6.45%WHWK-3.13%
12 Health Care Stocks Moving In Tuesday's Intraday Sessionbenzinga_article·Jul 7 at 12:05 PMCRNX+0.10%AKTX-6.45%
Akari Therapeutics Appoints Former AACR President and Renowned Oncology Drug Development Leader, Patricia LoRusso,., to Scientific Advisory Board | AKTX Stock NewsStockTitan·Jul 6 at 11:55 PMAKTX-6.45%
Akari Therapeutics holds annual general meeting, shareholders vote on director re-electionsPUBT·Jul 2 at 04:26 PMAKTX-6.45%
Akari Therapeutics completes USD 5.5 million PIPE private placement financingPUBT·Jun 29 at 07:45 AMAKTX-6.45%
Akari Therapeutics Completes Previously Announced PIPE, Strengthening Balance Sheet Ahead of Potential Key Clinical and Regulatory Milestones | AKTX Stock NewsStockTitan·Jun 28 at 11:45 PMAKTX-6.45%
